OBJECTIVE: Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD. METHODS: A discovery cohort of 70 PD patients was recruited. Cognitive status was evaluated with the Mattis Dementia Rating Scale-2 (DRS) at baseline and on annual follow-up visits, and baseline plasma levels of 102 proteins were determined with a bead-based immunoassay. Using linear regression, we identified biomarkers of CI in PD, that is, proteins whose levels correlated with cognitive performance at baseline and/or cognitive decline at follow-up. We then replicated the association between cognitive performance and levels of the top biomarker, using a different technical platform, with a separate cohort of 113 PD patients. RESULTS: Eleven proteins exhibited plasma levels correlating with baseline cognitive performance in the discovery cohort. The best candidate was epidermal growth factor (EGF, p < 0.001); many of the other 10 analytes covaried with EGF across samples. Low levels of EGF not only correlated with poor cognitive test scores at baseline, but also predicted an 8-fold greater risk of cognitive decline to dementia-range DRS scores at follow-up for those with intact baseline cognition. A weaker, but still significant, relationship between plasma EGF levels and cognitive performance was found in an independent replication cohort of 113 PD patients. INTERPRETATION: Our data suggest that plasma EGF may be a biomarker for progression to CI in PD.
OBJECTIVE: Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD. METHODS: A discovery cohort of 70 PDpatients was recruited. Cognitive status was evaluated with the Mattis Dementia Rating Scale-2 (DRS) at baseline and on annual follow-up visits, and baseline plasma levels of 102 proteins were determined with a bead-based immunoassay. Using linear regression, we identified biomarkers of CI in PD, that is, proteins whose levels correlated with cognitive performance at baseline and/or cognitive decline at follow-up. We then replicated the association between cognitive performance and levels of the top biomarker, using a different technical platform, with a separate cohort of 113 PDpatients. RESULTS: Eleven proteins exhibited plasma levels correlating with baseline cognitive performance in the discovery cohort. The best candidate was epidermal growth factor (EGF, p < 0.001); many of the other 10 analytes covaried with EGF across samples. Low levels of EGF not only correlated with poor cognitive test scores at baseline, but also predicted an 8-fold greater risk of cognitive decline to dementia-range DRS scores at follow-up for those with intact baseline cognition. A weaker, but still significant, relationship between plasma EGF levels and cognitive performance was found in an independent replication cohort of 113 PDpatients. INTERPRETATION: Our data suggest that plasma EGF may be a biomarker for progression to CI in PD.
Authors: Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak Journal: Neurobiol Aging Date: 2003 Mar-Apr Impact factor: 4.673
Authors: J A Lucas; R J Ivnik; G E Smith; D L Bohac; E G Tangalos; E Kokmen; N R Graff-Radford; R C Petersen Journal: J Clin Exp Neuropsychol Date: 1998-08 Impact factor: 2.475
Authors: D Aarsland; I Litvan; D Salmon; D Galasko; T Wentzel-Larsen; J P Larsen Journal: J Neurol Neurosurg Psychiatry Date: 2003-09 Impact factor: 10.154
Authors: I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada Journal: Neurology Date: 2005-10-19 Impact factor: 9.910
Authors: Elizabeth A McAninch; Sungro Jo; Nailliw Z Preite; Erzsébet Farkas; Petra Mohácsik; Csaba Fekete; Péter Egri; Balázs Gereben; Yan Li; Youping Deng; Mary-Elizabeth Patti; Chantal Zevenbergen; Robin P Peeters; Deborah C Mash; Antonio C Bianco Journal: J Clin Endocrinol Metab Date: 2015-01-08 Impact factor: 5.958
Authors: James F Morley; Sharon X Xie; Howard I Hurtig; Matthew B Stern; Amy Colcher; Stacy Horn; Nabila Dahodwala; John E Duda; Daniel Weintraub; Alice S Chen-Plotkin; Vivianna Van Deerlin; Dana Falcone; Andrew Siderowf Journal: Mov Disord Date: 2012-02-16 Impact factor: 10.338
Authors: Judy K Qiang; Yvette C Wong; Andrew Siderowf; Howard I Hurtig; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski; Dora Yearout; James B Leverenz; Thomas J Montine; Matt Stern; Susan Mendick; Danna Jennings; Cyrus Zabetian; Ken Marek; Alice S Chen-Plotkin Journal: Ann Neurol Date: 2013-08-06 Impact factor: 10.422